An Open-label, Multi-center Rollover Protocol for Patients Who Have Participated in a Novartis-sponsored Ribociclib (LEE011) Study and Are Continuing to Benefit From Ribociclib as Single Agent or in Combination With Other Investigational Treatments
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Ribociclib (Primary)
- Indications Breast cancer; Gastrointestinal cancer; Glioma; Head and neck cancer; Liposarcoma; Liver cancer; Lymphoma; Malignant melanoma; Meningioma; Non-small cell lung cancer; Prostate cancer; Solid tumours; Teratoma
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 23 Feb 2018 Planned End Date changed from 27 Apr 2022 to 29 May 2019.
- 23 Feb 2018 Planned primary completion date changed from 27 Apr 2022 to 29 May 2019.
- 21 Nov 2016 Status changed from not yet recruiting to recruiting.